Download Adams, Sarah F. BIOGRAPHICAL SKETCH Sarah Foster Adams

Adams, Sarah F.
Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
NAME
POSITION TITLE
Sarah Foster Adams
Assistant Professor, Gynecologic Oncology
The Victor and Ruby Hansen Surface Professor
in Ovarian Cancer Research
P30 Role: Full Member Translational Cancer
Biology & Signaling
eRA COMMONS USER NAME
SARAHADAMS
EDUCATION/TRAINING
A.
INSTITUTION AND LOCATION
DEGREE
(if applicable)
YEAR(s)
FIELD OF STUDY
Harvard University, Cambridge, MA
University of Chicago, Pritzker School, Chicago, IL
University of Chicago Hospitals, Chicago IL
University of Pennsylvania, Philadelphia, PA
BA
MD
Residency
Fellowship
1996
2001
2005
2009
Biochemistry
Medicine
Obstetrics and Gynecology
Gynecologic Oncology
Personal Statement:
I am a gynecologic oncologist with a research interest in tumor immunology and the development of novel
strategies for the treatment of ovarian cancer. The focus of my lab is to evaluate the role of the immune system in
shaping patterns of disease spread and recurrence, as well as response to therapy using ovarian tumor models.
Specifically, we are testing the hypothesis that local immune tolerance in the peritoneal cavity contributes to the
dominant patterns of cancer metastasis and the development of peritoneal carcinomatosis, which is responsible
for the major morbidity and mortality seen in women with this disease. Recently we have begun an investigation of
the impact of surgery on the peritoneal environment, and the potential for designing perioperative treatment
protocols with long-term survival benefit. This grew out of our interest in the impact of the peritoneal environment
on ovarian cancer growth and dissemination, and our overall goal is to identify novel immunologic targets to
restrict intraperitoneal cancer dissemination and improve both the quality of life and overall survival of women with
ovarian cancer.
B. Positions and Honors:
Positions and Employment
2005- 2006
Assistant Professor, Department of OB/Gyn, University of Illinois Hospital, Chicago
2006- 2009
Clinical Instructor, Gynecologic Oncology, The University of Pennsylvania Hospitals
2009- 2012
Assistant Professor, Gynecologic Oncology, The University of Pennsylvania
2012- Present
Assistant Professor, Division of Gynecologic Oncology, The Victor and Ruby Hansen
Surface Professor in Ovarian Cancer Research, The University of New Mexico
Other Experience and Professional Memberships
2012
Member, American Association of Immunologists
2009
Diplomate, American Board of Obstetrics and Gynecology
2009
Fellow, American Congress of Obstretrics and Gynecology
2009
Candidate member, Society of Gynecologic Oncologists
2007
Member, American Society of Clinical Oncology
Awards and Honors
2013
Palliative Care Superstar Award, UNM Hospitals
2012
Ruby and Victor Hansen Surface Professor of Ovarian Cancer Research
2012
Clarence C. Briscoe Award for Excellence in the Teaching and Practice of OB/GYN
2012
Recognized as a “Health Care Hero”, Pennsylvania Hospital
2011
Top Reviewer, Gynecologic Oncology, Elsevier
2010
ACOG Council on Resident Education National Faculty Teaching Award
3
Program Director/Principal Investigator (Last, First, Middle):
2009-2013
2008
2005
2005
2003
2003
2003
2001
1997-2001
1993-1996
1993-1996
1992-1993
Adams, Sarah F.
NIH Loan Repayment Award and Renewal
Scholar-in-Training Award, American Association for Cancer Research
Arnold P. Gold Foundation Resident Physician Award for Humanism & Excellence in
Medicine
Academic Chief Resident, Department of Obstetrics and Gynecology, University of Chicago
Arnold P. Gold Foundation Resident Physician Award for Humanism & Excellence in
Medicine
Golden Apple Resident Teaching Award
First Place, Resident Research Presentation, Chicago Association of Gynecologic
Oncologists
AMWA Academic Excellence Award
Thomas Brown McClelland Medical Scholarship
Aggasiz Academic Scholarship, Harvard University
Harvard University Honor Scholarship
Byrd Honor Scholarship
C. Selected peer-reviewed publications:
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Coukos G,
Adams S. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gyn
Oncology posted online March 29, 2014.
2. Ramirez PT, Adams S, Boggess JF, et al.Robotic-Assisted Surgery in Gynecologic Oncology: A Society of
Gynecologic Oncology Consensus Statement Developed by the Society of Gynecologic Oncology's Clinical
Practice Robotics Task Force. Gynecologic Oncology 2012 February; 124(2): 180-4.
3. Hwang WT*, Adams SF*, Tahirovic E, Hagemann I, Coukos G. Prognostic Significance of Tumor-infiltrating
Tcells in Ovarian Cancer: a Meta-analysis. Gynecologic Oncology 2012 February 124(2); 192-8.
Published with an editorial; *Authors contributed equally. PMC3298445.
4. Adams S, Marsh E, Elmasri W, Halberstadt SM, VanDecker S, Sammel MD, Bradbury A, Daly M Karlan B,
Rubin SC. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations
treated for recurrent epithelial ovarian cancer.Gynecol Oncology 2011 Dec;123(3):486-91. Epub 2011 Sep
25. PMC3260049.
5. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya
K, Birrer MJ, Gimotty PA, Coukos G. Tissue-Based Immune Monitoring I: Tumor Core Needle Biopsies
Allow In-Depth Interrogation of the Tumor Microenvironment. Cancer Biol Ther. 2011 Aug 15;12(4):35766. Epub 2011 Aug 15. PMC3173733.
6. Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, June C, Powell D,
Coukos G. Time-dependent Cytotoxic Drugs Selectively Cooperate with IL-18 for Cancer Chemoimmunotherapy. J Transl Med. 2011 May 25;9:77. PMC3118128.
7. Cardenas-Goicoechea SJ, Adams S, Bhat SB, Randall T. Surgical outcomes of robotic-assisted surgical
staging for endometrial cancer are equivalent to traditional laparoscopic staging at a minimally invasive
surgical center. Gynecologic Oncology 2010 May; 117(2): 224-8. PMC2896309.
8. Davis MA, Adams SF, Eun D, Lee D, Randall TC. Robotic-assisted laparoscopic exenteration in recurrent
cervical cancer: robotics improved the surgical experience for two women with recurrent cervical cancer.
Am J Obstet Gynecol. 2010 Jun;202(6):663.e1.
9. Robinson B, Liao JB, Adams SF, Randall TC. Vaginal Cuff Dehiscence After Robotic Total Laparoscopic
Hysterectomy. Am J of Obstet Gynecol. 2009 August; 114(2Pt1):369-71. PMC2896382.
10. Alagkiozidis I, Facciabene A, Carpentino C, Benencia F, Jonak Z, Adams S, Carroll RG, Gimotty P,
Hammond R, Danet-Desnoyres G, June CH, Powell DJ, Coukos G. Increased immunogenicity of surviving
tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Translational Medicine 2009
Dec 10; 7: 104. PMC2797002.
11. Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty
P, Coukos G. Intraepithelial T cells and tumor proliferation: interactions and impact on benefit from surgical
cytoreduction in advanced serous ovarian cancer. Cancer July 2009. PMC2754811.
1.
Program Director/Principal Investigator (Last, First, Middle):
Adams, Sarah F.
12. Zhang L, Volinia S, Bonome T, Calin GA, Yang N , Atlamazoglou V, Liu C-G, Giannakakis A, Greshock J,
Hasegawa K, Johnstone CN, Adams S, Lassus H, Huang J, Megraw MS, Thireou T, Liang S, Leminen A,
Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, Huang Q, Bützow R, DeMichele A, Rustgi AK,
Weber BL, Birrer MJ, Hatzigeorgiou AG,Croce CM, Coukos G. Genomic and epigenetic lterations
deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 105(19):
7004-9, 2008. PMC2383982.
13. Adams SF, Hickson JA, Hutto JY, Montag A, Lengyel E, Yamada SD. PDGFR-a as a potential therapeutic
targetin uterine sarcomas. Gynecologic Oncology 104:524-8, March, 2007.
14. Adams S, Gallagher J, Mahowald M. Refusal of treatment during pregnancy. Clinics in Perinatology 30:
127-140, March 2003.
15. Yamada SD, Hickson JA, Hrobowski, Y, Vander Griend DJ, Benson D, Montag A, Karrison T, Huo D,
Rutgers J,Adams S, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a
metastasis suppressorgene in human ovarian carcinoma. Cancer Research 62:6717-6723, November,
2002.
16.Adams SF, Yamada SD, Montag A, Rotmensch J. An alpha-fetoprotein-producing hepatoid
adenocarcinoma of the endometrium. Gynecologic Oncology 83:418-421, November 2001.
17. Betz JM, Gay ML, Mossoba MM, Adams S, Portz BS. Chiral gas chromatographic determination of
ephedrinetype alkaloids in dietary supplements containing Ma Huang. Journal AOAC International
80(2):303-315, March-April 1996.
18. Mossoba MM, Adams S, Roach JA, Trucksess MW. Analysis of trichothecene mycotoxins in contaminated
grains by gas chromatography/matrix isolation/fourier transform infrared spectroscopy and gas
chromatography/massspectrometry. Journal AOAC International 79(5):1116-1123, Sept-Oct 1996.
D. Research Support
Ongoing Research Support:
Liz Tilberis Scholar Award (PI Adams)
1/31/11-1/30/2015
Ovarian Cancer Research Fund
Title: Development of combination therapy with PARP inhibitors and anti-CTLA4 antibody for the treatment of
women with hereditary ovarian cancer.
Goals: To use PARP inhibitors to sensitize BRCA1- or sporadic ovarian cancers to immune therapy with
antibodies targeting CTLA4, PD1, or LAG3, to enhance the activity of tumor specific T cells and improve
survival outcomes
MSRG-12-163-01-LIB (PI Adams)
9/1/12-8/31/17
American Cancer Society
Title: Intestinal immune tolerance promotes ovarian cancer dissemination.
Goals: To test a novel paradigm for the dominant pattern of ovarian cancer metastasis and recurrence in the
peritoneal cavity by investigating a functional interaction between tumor cells and tolerogenic intestinal
leukocytes.
Completed Research Support:
University of Pennsylvania Research Foundation Award (PI Adams)
7/1/11-6/30/12
A pilot study to evaluate intraperitoneal leukocyte function and trafficking in the setting of ascites and peritoneal
carcinomatosis in a mouse model of ovarian cancer
The Kaleidoscope of Hope Ovarian Cancer Foundation (PI Adams)
8/1/10-6/1/13
“Characterization of the enhanced anti-tumor activity of Doxil in women with hereditary ovarian cancer”
Ovarian Cancer SPORE Pilot Project Award (PI Adams)
9/1/09-8/31/10
“Immunotherapy for advanced or recurrent ovarian cancer using autologous ascites cells”
Paul Calabresi Award for Research in Clinical Oncology (NIH K12)
7/1/09-6/30/12
Program Director/Principal Investigator (Last, First, Middle):
ASCO Cancer Foundation Young Investigator Award (PI Adams)
“Optimization of Personalized Immunotherapy for Women with
Cells.”
Adams, Sarah F.
7/1/09-6/30/10
Ovarian Cancer Using Autologous Ascites
Sandy Rollman Ovarian Cancer Foundation (PI Adams)
8/1/08-7/31/09
“Development of Personalized Immunotherapy for Ovarian Cancer Using Autologous Ascites Cells”
Florence and Marshall Schwid Ovarian Cancer Grant, (PI Adams)
7/1/06-6/30/08
Gynecologic Cancer Foundation “Development of Immunotherapy for Ovarian Cancer using Ascites AntigenPresenting Cells”